Eligibility criteria for omalizumab treatment in Turkey were age ≥ 12 years, uncontrolled symptoms, history of multiple asthma attacks despite high-dose ICS-LABA and/or leukotriene receptor antagonist treatment, forced expiratory volume in 1 second (FEV1) <80%, perennial allergen sensitivity, and total IgE level between 30 and 1500 IU/mL. This evidence concerns the gene IGHE and asthma.